Condition (MeSH)
Kartagener Syndrome
ClinicalTrials.gov lists 21 trials for Kartagener Syndrome or a narrower condition beneath it. ReCode Therapeutics has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
21 of the 21 trials are tagged with Kartagener Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Kartagener Syndrome trials start? (14)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 2 |
| 2023 | 2 |
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 3 |
| 2019 | 1 |
| 2015 | 1 |
| 2014 | 1 |
| 2013 | 2 |
Showing 10 of 14 earlier years.
No forecast is made for this condition: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 21 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Kartagener Syndrome trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Not applicable | 1 |
| Observational | 17 |
How many Kartagener Syndrome trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 4 |
| Active, not recruiting | 1 |
| Completed | 16 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Kartagener Syndrome trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| ReCode Therapeutics | 4 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 1 |
Interventions as named in the registry (4)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| RCT1100 | 3 |
| data collection | 1 |
| Home-based therapy | 1 |
| BLOOD SAMPLE | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Kartagener Syndrome? (95)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| European Respiratory Society and American Thoracic Society guidelines for the diagnosis of primary ciliary dyskinesia. | The European respiratory journal | 2025 | Yes |
| Oral Health Status and Oral Health-Related Quality of Life in Children With Primary Ciliary Dyskinesia. | Pediatric pulmonology | 2025 | Yes |
| Primary Ciliary Dyskinesia in Adult Bronchiectasis: Data from the German Bronchiectasis Registry PROGNOSIS. | Chest | 2024 | Yes |
| Nasal nitric oxide measurement in children for the diagnosis of primary ciliary dyskinesia: European Respiratory Society technical standard. | The European respiratory journal | 2023 | Yes |
| Cystic fibrosis and primary ciliary dyskinesia: Similarities and differences. | Respiratory medicine | 2023 | Yes |
Showing 5 of 95 publications.
Prevalence (2)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Primary ciliary dyskinesia | Prevalence at birth | 1-9 / 100 000 | Europe | Not stated | Unspecified |
| Primary ciliary dyskinesia | Point prevalence | 1-5 / 10 000 | Pakistan | Not stated | Unspecified |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, rare-disease identity, and sub-conditions in mesh.